Streetbeat News

Stock Prices

RMAX

RE/MAX Holdings shares experienced an uptick following a report indicating that February's existing home sales surpassed estimates. This positive news suggests a healthier real estate market, potentially benefiting companies like RE/MAX involved in property sales.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 2:07 pm

SHIBUSD

Shiba Inu (SHIB) sees a 5% price increase amid a 15.8% rise in meme coin market cap. Significant acquisitions by whales, including a $8.62 million purchase, and a shift from long-term to short-term holders are noted. Despite concerns over long-term holder reduction, the Shiba community remains optimistic, with SHIB's marketing lead and Crypto.com recognizing its potential.

Portfolio Pulse from Khyathi Dalal

March 21, 2024 | 2:07 pm

CBRE

Over the past 5 years, CBRE Group (NYSE:CBRE) has outperformed the market with an annualized return of 14.86%, turning a $1000 investment into $2,021.33. The company currently has a market capitalization of $29.24 billion.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:01 pm

PK

Analysts have mixed views on Park Hotels & Resorts (NYSE:PK), with 6 recent ratings ranging from bullish to indifferent. The average 12-month price target is $20.5, up 14.97% from the previous $17.83. Analysts from firms like Wells Fargo, Truist Securities, and Deutsche Bank have raised their price targets, reflecting optimism. Park Hotels & Resorts, focusing on high-quality assets in the U.S., shows a strong market presence but faces revenue challenges with a -1.2% growth over 3 months. However, its financial performance is solid, with a high net margin of 28.16% and an ROE of 4.74%.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:01 pm

MUR

Analysts have recently adjusted their ratings and price targets for Murphy Oil (NYSE:MUR), showing a mix of bullish and bearish sentiments. The average 12-month price target is now $49.00, down 3.54% from previous estimates, with a high of $53.00 and a low of $43.00. The company faces challenges in revenue growth, net margin, ROE, and ROA, indicating potential difficulties ahead. Despite these challenges, some analysts have raised their price targets, while others have lowered them, reflecting a diverse set of opinions on the company's future performance.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

MBRX

Moleculin Biotech (NASDAQ:MBRX) is scheduled to release its quarterly earnings report on March 22, 2024, with an expected EPS of $-0.20. Historical data shows mixed reactions to past earnings, with the stock price often dropping post-announcement. Shares have declined 56.44% over the last year, indicating a bearish outlook among long-term investors.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

FN

Fabrinet (NYSE:FN) has been analyzed by 4 analysts, showing diverse perspectives with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for FN is now $215.0, marking an 11.69% increase from the previous target of $192.50. Analyst actions include ratings adjustments and price target changes, reflecting updated market conditions and company performance. Fabrinet's financial health indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management suggest a strong market position and financial health.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

STRR

Star Equity Holdings (NASDAQ:STRR) is scheduled to release its quarterly earnings report on March 22, 2024, with an expected EPS of $-0.08. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for future growth. Historical data shows mixed reactions in stock price to past earnings performances, with minor fluctuations following the announcements. Shares have seen a 13.43% increase over the last 52 weeks, indicating a generally positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

XHR

Analysts have recently updated their evaluations and price targets for Xenia Hotels & Resorts (NYSE:XHR), reflecting a mix of opinions but generally indicating a positive outlook. The average 12-month price target has been raised to $16.12, marking a 13.12% increase from the previous target. This adjustment comes after a period of varied ratings, with the most recent consensus being indifferent. Despite the optimistic price targets, Xenia faces challenges such as a decline in revenue growth, below-average net margin, and ROE, indicating potential difficulties ahead.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm

HUMA

Humacyte (NASDAQ:HUMA) is scheduled to release its quarterly earnings report on Friday, 2024-03-22, with an estimated EPS of $-0.24. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, Humacyte's stock price has shown sensitivity to both earnings outcomes and forward guidance. The stock was trading at $3.51 as of March 20, reflecting a 24.4% increase over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 2:00 pm